Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.

Wire MB, Li X, Zhang J, Sallas W, Aslanis V, Ouatas T.

Clin Pharmacol Ther. 2018 Dec;104(6):1199-1207. doi: 10.1002/cpt.1066. Epub 2018 Apr 17.

PMID:
29536526
2.

Erratum for Wire et al., Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.

Wire MB, Fang L, Hussaini A, Kleha JF, Theodore D.

Antimicrob Agents Chemother. 2015 May;59(5):2969. doi: 10.1128/AAC.00567-15. No abstract available.

3.

Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.

Zhang J, Thapar M, Farrell C, Wire MB.

Pharm Res. 2015 Jun;32(6):2015-28. doi: 10.1007/s11095-014-1594-x. Epub 2014 Dec 23.

PMID:
25534682
4.

Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.

Barbour AM, Gibiansky L, Wire MB.

J Clin Pharmacol. 2014 Feb;54(2):206-14. doi: 10.1002/jcph.205. Epub 2013 Nov 5.

PMID:
25272370
5.

Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.

Wire MB, Fang L, Hussaini A, Kleha JF, Theodore D.

Antimicrob Agents Chemother. 2014 Nov;58(11):6704-9. doi: 10.1128/AAC.03091-14. Epub 2014 Aug 25. Erratum in: Antimicrob Agents Chemother. 2015 May;59(5):2969.

6.

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.

Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamarirt DP, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Perger T, Sievers J.

Pediatr Infect Dis J. 2014 Jan;33(1):50-6. doi: 10.1097/INF.0b013e3182a1126a.

7.

Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.

Cotton M, Cassim H, Pavía-Ruz N, Garges HP, Perger T, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Sievers J, Cheng K.

Pediatr Infect Dis J. 2014 Jan;33(1):57-62. doi: 10.1097/INF.0b013e3182a1123a.

8.

Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.

Wire MB, McLean HB, Pendry C, Theodore D, Park JW, Peng B.

Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51. doi: 10.1128/AAC.05214-11. Epub 2012 Mar 5.

10.

Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.

Deng Y, Madatian A, Wire MB, Bowen C, Park JW, Williams D, Peng B, Schubert E, Gorycki F, Levy M, Gorycki PD.

Drug Metab Dispos. 2011 Sep;39(9):1734-46. doi: 10.1124/dmd.111.040170. Epub 2011 Jun 6.

PMID:
21646437
11.

Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.

Kazmierski WM, Anderson DL, Aquino C, Chauder BA, Duan M, Ferris R, Kenakin T, Koble CS, Lang DG, McIntyre MS, Peckham J, Watson C, Wheelan P, Spaltenstein A, Wire MB, Svolto A, Youngman M.

J Med Chem. 2011 Jun 9;54(11):3756-67. doi: 10.1021/jm200279v. Epub 2011 May 17.

PMID:
21539377
12.

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.

Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, Lee E.

Br J Clin Pharmacol. 2011 Aug;72(2):321-9. doi: 10.1111/j.1365-2125.2011.03972.x.

13.

Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.

Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E.

J Clin Pharmacol. 2011 Oct;51(10):1403-17. doi: 10.1177/0091270010383019. Epub 2010 Dec 8.

PMID:
21148042
14.

Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.

Cohen C, Dejesus E, Lamarca A, Young B, Yau L, Patel L, Vavro C, Wire MB, Wannamaker P, Shaefer M.

HIV Clin Trials. 2010 Sep-Oct;11(5):239-47. doi: 10.1310/hct1105-239.

PMID:
21126954
15.

Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.

Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, Park JW.

J Clin Pharmacol. 2011 May;51(5):739-50. doi: 10.1177/0091270010372106. Epub 2010 Jul 27.

PMID:
20663991
16.

Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.

Matthys G, Park JW, McGuire S, Wire MB, Zhang J, Bowen C, Williams D, Jenkins JM, Peng B.

Br J Clin Pharmacol. 2010 Jul;70(1):24-33. doi: 10.1111/j.1365-2125.2010.03646.x.

17.

Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.

Matthys G, Park JW, McGuire S, Wire MB, Bowen C, Williams D, Jenkins J, Peng B.

J Clin Pharmacol. 2011 Mar;51(3):301-8. doi: 10.1177/0091270010368677. Epub 2010 Apr 23.

PMID:
20418510
18.

Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.

Pérez-Elías MJ, Morellon ML, Ortega E, Hernández-Quero J, Rodríguez-Torres M, Clotet B, Felizarta F, Gutiérrez F, Pineda JA, Nichols G, Lou Y, Wire MB.

Antimicrob Agents Chemother. 2009 Dec;53(12):5185-96. doi: 10.1128/AAC.00632-09. Epub 2009 Aug 10.

19.

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.

J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10.

PMID:
19515730
20.

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.

Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, Collins DA, Kapsi SG, Jenkins JM.

Clin Ther. 2009 Apr;31(4):764-76. doi: 10.1016/j.clinthera.2009.04.010.

PMID:
19446149
21.

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.

Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.

Pharmacotherapy. 2008 Jul;28(7):863-74. doi: 10.1592/phco.28.7.863.

PMID:
18576901
22.

Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.

Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW.

Antimicrob Agents Chemother. 2007 Aug;51(8):2982-4. Epub 2007 May 21.

23.

Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.

Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA; COL10053 Study Team.

Antimicrob Agents Chemother. 2007 Feb;51(2):560-5. Epub 2006 Nov 6.

24.

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

DeJesus E, Piliero PJ, Summers K, Wire MB, Stein DS, Masterman A, Lou Y, Min SS, Shelton MJ.

Antimicrob Agents Chemother. 2006 Sep;50(9):3157-9.

25.

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.

Shelton MJ, Ford SL, Borland J, Lou Y, Wire MB, Min SS, Xue ZG, Yuen G.

J Acquir Immune Defic Syndr. 2006 May;42(1):61-7.

PMID:
16639341
26.

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.

Antimicrob Agents Chemother. 2006 Apr;50(4):1578-80.

27.

Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.

Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.

Antimicrob Agents Chemother. 2006 Mar;50(3):928-34.

28.

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Wire MB, Shelton MJ, Studenberg S.

Clin Pharmacokinet. 2006;45(2):137-68. Review.

PMID:
16485915
29.

Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.

Ford SL, Wire MB, Lou Y, Baker KL, Stein DS.

Antimicrob Agents Chemother. 2005 Jan;49(1):467-9.

30.

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.

Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, Christopher J, Fuchs EJ, Snidow JW.

Pharmacotherapy. 2004 Sep;24(9):1110-21.

PMID:
15460171
31.

A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ.

Clin Infect Dis. 2004 Aug 15;39(4):591-4. Epub 2004 Jul 26.

PMID:
15356829
32.

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y, Stein DS.

AIDS. 2004 Apr 9;18(6):897-907.

PMID:
15060437
33.

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ.

Antimicrob Agents Chemother. 2004 Jan;48(1):116-23.

34.
35.

Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

Chaudry NI, Eron JJ, Naderer OJ, Pereira AS, Wire MB, Fiscus SA, Kashuba AD.

Clin Infect Dis. 2002 Sep 15;35(6):760-2. Epub 2002 Aug 23.

PMID:
12203175
36.

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.

Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL.

Antimicrob Agents Chemother. 2002 Sep;46(9):2969-76.

Supplemental Content

Support Center